ABACAVIR AND LAMIVUDINE

Pre-Launch

abacavir; lamivudine

Cipla

NDAORALTABLET, FOR SUSPENSION

Lifecycle

Pre-Launch

Clinical Trials

Mechanism of Action

HIV-1 [see ] .

Indications (2)

human immunodeficiency virus type 1 (HIV-1) infection combination with other antiretroviral agents for the treatment of HIV-1 infection

Clinical Trials (1)

NCT00094367Phase 3Completed

A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)

Started Jul 2004

900 enrolled

HIV Infection

Company

Cipla

India - Mumbai

External Resources

DailyMed

Full prescribing information

FDA Drugs@FDA

FDA approval history

RxNorm

Drug nomenclature & identifiers